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Using Mass Spectrometry for Drug Metabolism Studies,
edited by Walter A. Korfmacher, is a timely testament
showing the availability of robust mass spectrometers,
rugged chromatographic methods, sample preparation,
and sample introduction techniques for improving all
phases of drug discovery and development in an effort
to produce safer and efficacious drugs. This book is
clear and concise, written in a manner that is not
overwhelming for a novice mass spectrometrist and not
too simplistic for a seasoned mass spectrometrist. The
book, divided into twelve chapters and authored by
leaders in the field, eloquently conveys the art of mass
spectrometry as it applies to drug metabolism studies
and the quest to discover and develop new, safer, and
efficacious medicines.
Chapter 1, entitled “Bioanalytical Assays in a Drug
Discovery Environment”, is authored by the editor.
The focus of this chapter is on the use of LC-MS/MS
for discovery stage drug-metabolism applications,
especially for analysis of in vivo pharmacokinetic
(PK) samples. Applications provided in this chapter
underscore the need for faster liquid chromatography
(LC)-tandem mass spectrometry (MS/MS) assays that
can provide high quality data in a high throughput
manner to impact the timelines and reduce the cost of
bringing safe and effective drugs to patients. All
aspects of LC-MS/MS assays and ways to improve
throughput are discussed and include the following:
(1) sample collection techniques, (2) sample prepara-
tion/processing techniques, and (3) various methods
to maximize MS assay time. Although covered in
detail in latter chapters, Chapter 1 also introduces the
reader to LC-MS/MS assay development issues re-
lated to interferences from drug metabolites and
background matrix ions/matrix ion suppression. For
reference, a list of putative metabolites that could
potentially interfere with assay through coelution
and/or in-source fragmentation is provided. Addi-
tionally, topics introduced include higher mass reso-
lution triple quadrupole and quadrupole linear ionPublished online June 5, 2006
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(J Am Soc Mass Spectrom 2006, 17, 1188–1192)trap mass spectrometers, atmospheric pressure chem-
ical ionization (APCI), atmospheric pressure photo-
ionization (APPI), chip-based nanospray ion sources,
automated MS/MS method development and metab-
olite identification software, and the potential utility
of the above mentioned techniques in quantitative
bioanalysis of drugs.
In the Current Practices section, the major steps in
the discovery bioanalytical process including animal
dosing, sample tracking, standard-curve preparation,
sample preparation, LC-MS/MS assay development,
data processing and PK report preparation, and com-
mon industry practices for streamlining these steps
are very well presented. This section also provides
the reader with a series of stages through which
compounds must go before being recommended for
full development. These stages include chemistry/
synthesis, biology-high throughput screen, in vitro
stability screen, caco-2 absorption screen, P450 en-
zyme inhibition screen, oral dose-rat PK screen (Level
I), oral/IV dose rat/dog/monkey PK studies (Level
II), discovery metabolite ID studies, special PK stud-
ies (Level III), and development studies (Level IV).
LC-MS/MS assays involved in the latter four stages
are categorized into four levels, and rules associated
with these assays are tabulated and described in
detail. This section will be of significance to those
who want to establish the stage at which an LC-
MS/MS assay without any quality control (QC) sam-
ples and two-point standard curve is sufficient to test
a large number of compounds, and at which stage it
will be necessary to comply with good laboratory
practice (GLP) and follow other guidelines set forth
by regulatory agencies such as the food and drug
administration (FDA).
Chapter 2, “Drug Metabolism In Vitro and In Vivo
Results: How Do These Data Support Drug Discov-
ery?” is written by Thomas N. Thompson. This chap-
ter serves as a very good review of overall drug
metabolism and pharmacokinetics (DMPK) for any
newcomer to the field, but fails to make a strong
connection on how mass spectrometry measurements
can be used to elucidate some of the DMPK proper-
ties discussed. Nevertheless, this chapter is important
for mass spectrometry practitioners to understand
the key factors and relationship between a compound
structure and its DMPK properties. DMPK properties
defined and explained include oral dose bioavailabil-
ity, half-life, fraction absorbed, clearance, and volume
of distribution. In separate sections, the later three
properties are further elaborated. An important mes-
sage conveyed is that about 40, 30, 20, and 10% of the
drug candidates fail owing to poor pharmacokinetics
properties, poor clinical efficacy, toxicity, and other
unspecified causes, respectively. These compound
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try recognize that it is necessary to weed out the
compounds with poor DMPK properties early in the
drug development program and follow the motto
“fail fast, but cheap.” The author has done an excel-
lent job in describing how pharmaceutical scientists
are adhering to this motto by inventing and adapting
innovative mass spectrometry methods with high
accuracy, enhanced sensitivity, and higher through-
put over traditional techniques.
In Chapter 3 “High Throughput Strategies for In
Vitro ADME Assays: How Fast Can We Go?,” Daniel
B. Kassel starts by presenting biopharmaceutical
properties of an ideal development drug candidate
and, to assist the reader, a tabulated list of these
properties. This chapter further points out that to
select compounds with desirable biopharmaceutical
properties, it is important to implement studies that
assess absorption, distribution, metabolism, and ex-
cretion (ADME) properties of compounds early in the
drug discovery program. Among the ADME proper-
ties, absorption and metabolism properties have been
identified as key properties to profile at earlier stages
of drug discovery. In vitro based screens for meta-
bolic stability, cytochrome P450 inhibition, cell per-
meability, solubility, plasma stability, and plasma
protein binding are important attributes to weed out
compounds that are metabolized rapidly and to select
or rank compounds for in vivo evaluations.
A large portion of ADME assays are now being
incorporated into drug discovery programs in a high
throughput mode because they have enhanced sensi-
tivity, selectivity, and ease of automation that is
available with LC-MS and LC-MS/MS in comparison
with traditional analytical methods (LC-UV, flores-
cence, NMR, etc.). In the next sections, high through-
put ADME assays are divided into serial, semi-
parallel, and parallel approaches and discussed in
detail. In the serial mode of operation, single au-
tosampler/HPLC column, and MS systems are used
and samples are injected one at a time, the strategies
used to increase throughput include fast chromatog-
raphy, automated data processing, and pooling strat-
egies (cassette dosing, pooling after individual dos-
ing, simple sample screens, etc.). In semi-parallel or
staggered parallel mode of operation, common delays
associated with sample loading and HPLC column
equilibration times are reduced by using two au-
tosamplers and columns in parallel with a single
triple quadrupole mass spectrometer. Parallel LC-MS
methods used to support high throughput ADME
assay are devised either using nonindexed or indexed
mass spectrometry. The general high throughput
parallel LC-MS system consists of a high-pressure
binary solvent delivery system, a multiple probe
autosampler, a switching valve, and a mass spec-
trometer. Multiple samples (8 or 4) are injected into
multiple injection ports (8 or 4) simultaneously and
delivered to multiple microbore columns (8 or 4). TheHPLC effluent from all columns is delivered to a
single mass spectrometer via either single (nonin-
dexed) or multiplexed (indexed or MUX)-ESI source.
By using parallel LC-MS approaches, as many as 5000
metabolic stability samples have been analyzed in a
single day. Advantages and limitations associated
with serial, semi-parallel, and parallel high through-
put strategies are well presented, and the reader will
learn how automated sample preparation, data acqui-
sition, and data processing have enabled the pharma-
ceutical industry to move most of the ADME studies
into the high throughput realm.
Chapter 4 “Matrix Effects: Causes and Solutions”
by Hong Mei is one of the most important chapters
for any new comer to the mass spectrometry field.
This chapter focuses on providing the reader with an
understanding of the ESI process. The ion-evapora-
tion and equilibrium-partitioning models, which are
used to predict the ESI response of an analyte based
on the properties and concentrations of the analyte
and coeluting components, are well presented. In a
nutshell, this chapter discusses the possible causes of
matrix effects by using the mechanism of ion forma-
tion in electrospray. Various approaches for evaluat-
ing matrix effects as well as strategies for overcoming
matrix effects are also discussed.
Chapter 5 “Direct Plasma Analysis Systems” by
Yunsheng Hsieh deals with on-line sample preparation
techniques that improve LC-MS and LC-MS/MS
throughput by eliminating the bottleneck associated
with off-line sample preparation. By using on-line solid-
phase extraction (SPE) procedures, analytes are deliv-
ered directly from a SPE cartridge into a mass spectrom-
eter. The steps associated with off-line sample
preparation (extraction, elution, evaporation, and re-
constitution) are thus eliminated.
The application of mass spectrometry for the anal-
ysis of acyl glucuronide conjugates is the topic of
Chapter 6 “Acyl Glucuronides: Assays and Issues” by
Sam Wainhaus. This chapter begins by describing
how acyl glucuronides are formed, and once formed
how these metabolites can undergo acyl migration,
and subsequently bind to protein and trigger immu-
notoxic reactions. The following section presents sev-
eral approaches that can be used to assess the toxic
nature of acyl glucuronides including mass spectrom-
etry based methods. The next sections show how
LC-MS and LC-MS/MS based methodologies can be
used to quantify acyl glucuronide formation, assess
the extent of acyl migration, and determine protein-
adduct formation. This chapter also details special
conditions that are used to collect and preserve acyl
glucuronides and slow down acyl migrations. This
chapter clearly points out that if appropriate sample
collection and storage conditions are not used, acyl
glucuronides can undergo hydrolysis and result in
underestimation of acyl glucuronide metabolites and
overestimation of its aglycone concentrations. The
reader is also presented with an acyl glucuronide risk
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immunotoxicity response and LC-MS/MS measured
parameters such as acyl glucuronide reactivity,
plasma level, and percent conversion.
In chapter 7 “Utilizing Higher Mass Resolution in
Quantitative Assays”, Xiaoying Xu discusses the new
mass spectrometry technology that can provide
higher mass resolution for quantitative assays. In
particular, triple quadrupole mass spectrometers
with enhanced mass resolving capabilities and quad-
rupole time-of-flight (Q-TOF) mass spectrometers are
compared and contrasted for PK applications. Tradi-
tionally, separation of an analyte from coeluting
matrix components and/or metabolites was achieved
by modifying the chromatographic conditions. How-
ever, HPLC method modifications come at the ex-
pense of time- and resource-consumption and most
often end up being methods with longer run times,
which are usually not suitable for high throughput
quantitative assays. The author shows several exam-
ples where utilization of higher mass resolution in
quantitative assays is advantageous over modifying
chromatographic conditions, changing ionization
methods, selecting different MRM or SRM ion pairs,
changing different mass spectrometers, or changing
the sample processing/clean-up methods.
Chapter 8 “Special Requirements for Metabolite
Characterization”, authored by Kathleen Cox, re-
views the challenges involved in selecting the appro-
priate mass spectrometry tools and techniques to get
information on the metabolic fate of drug candidates
in the high-throughput drug discovery environment.
A clear distinction is established between high
throughput based LC-MS/MS assays used for obtain-
ing absorption, enzyme inhibition, induction, and
other pharmacokinetic parameters and the complex,
low-throughput process associated with elucidating
biotransformation pathways of drug candidates. The
reader is introduced to the importance of determin-
ing reactive and toxic metabolic liabilities of drug
candidates and the necessity of conducting metabolic
profiling studies in several species to select appropri-
ate species for toxicological evaluation of drug can-
didates. Until recently, the complexity, availability of
limited supply of test compounds, and unavailability
of radiolabeled and/or stable labeled drug candi-
dates relegated metabolite profiling experiments to
the development phase of drug development. This
paradigm changed with the introduction of atmo-
spheric pressure ionization techniques (ESI, APCI,
and APPI) that allowed practical coupling of HPLCs
with mass spectrometers. This new technology has
paved the way for introduction of a plethora of
sensitive and selective quadrupole, ion trap, time-of-
flight, and hybrid mass spectrometers that can be
used for metabolite characterization. A section dedi-
cated to recent advances in mass spectrometry tech-
nology reviews the necessity of using complementary
MS instrumentation to understand completely themetabolic fate of drug candidates. Dr. Cox discusses
why triple quadrupole mass spectrometers are useful
in providing a first look at metabolite profiles of drug
candidates, and why ion trap mass spectrometers are
necessary to perform sequential MS/MS experiments
to narrow the potential sites of modification and
provide more complete structural information for
metabolites. This section concludes with the discus-
sion of recent advances in the accurate mass and
high-resolution mass spectrometers and their utility
in the identification of metabolites.
Next, a short section is dedicated to sample prep-
aration and discusses the difficulties associated with
developing sample preparation/clean-up methods
when the metabolic pathways of drug candidates are
unknown. The liquid chromatography (LC) section
discusses the importance of separating the metabo-
lites from matrix ions and points out the risks asso-
ciated with adopting high-throughput LC methods
for metabolite profiling experiments. These risks can
be overcome by utilizing fast scanning quadrupole
time-of-flight mass spectrometers to perform metab-
olite identification (ID) studies. Advantages associ-
ated with utilizing monolithic columns and the mer-
its of turbulent flow chromatography for metabolite
profiling experiments are also discussed briefly.
The section, covering the various metabolite ID
software programs, discusses the typical software
decision tree used for analyzing metabolite character-
ization study data. MS vendor-supplied software is
capable of interrogating LC-MS data, subtracting
matrix ions from the mass chromatogram, looking for
expected metabolites or characteristic isotopic pat-
terns, providing a list with potential metabolites, and
setting up MS/MS experiments to confirm the iden-
tity of the metabolites. Although scientist involve-
ment is crucial for metabolite characterization and
data interpretation, metabolite ID software can assist
to increase dramatically the throughput of discovery
metabolite ID studies. The current uses and technol-
ogy section discusses a tiered approach to metabolite
characterization and outlines the types of metabolism
experiments and mass spectrometry experiments that
are suitable at various stages of drug development.
This is a must-read chapter for all scientists who want
to embark on metabolite identification studies.
In Chapter 9 “APPI: A New Ionization Source for
LC and MS/MS Assays”, Yunsheng Hsieh introduces
the reader to atmospheric pressure photoionization
(APPI) technology. Before introducing the reader to
APPI, sections on early and recent development in
HPLC-MS interfaces briefly cover various ionization
techniques including thermospray, particle beam,
continuous-flow fast atom bombardment, sonic spray
ionization, ESI, and APCI. The main focus of the
chapter is the APPI technique and its application to
low-polarity analytes. This chapter also includes a
well-presented section on the dopant-assisted APPI,
and a section that focuses on techniques used in
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Overall, APPI capability is a must for a bioanalytical
tool box for tackling low-polarity analytes.
Chapter 10 “Q-Trap MS: A New Tool for Metabo-
lite Identification” by Gerard Hopfgartner and Man-
fred Zell focuses on the application of hybrid triple
quadrupole linear ion trap (QqLIT or Q-Trap) mass
spectrometer for drug metabolism studies. Overall,
Q-Trap is a versatile mass spectrometer that is suit-
able for all types of small molecule drug metabolism
and pharmacokinetics applications. Using two phar-
maceutical compounds, tolcapone and Compound A,
the authors compare qualitative and quantitative
capabilities of Q-Trap and contrast with those of
three-dimensional (3-D) trap, triple quadrupole, and
Q-TOF mass spectrometers. Examples show that in
comparison to 3-D traps, use of a quadrupole as a
linear ion trap significantly enhances the ion-trap
performance by increasing ion capacity, improving
injection and trapping efficiencies, and increasing
duty cycle. The low mass cut-off issues associated
with 3-D ion trap and how this limitation is overcome
in linear ion traps by using a quadrupole as a
collision cell are also covered. For quantitative exper-
iments, some of the nonlinearity associated with
space-charge effects, are eliminated by the increased
ion capacity of the quadrupole collision cell and the
incorporation of dynamic fill time (DFT). Further-
more, fast duty cycle provides the capability to
perform as many as 50 SRM transitions within a
second. Versatility of the Q-Trap mass spectrometer
for elucidating biotransformation pathways, in the
absence of a radiolabeled drug, is also demonstrated
by using various scan types. To guide the reader,
various Q-Trap scans and various information depen-
dent acquisition (IDA) scan combinations are tabu-
lated and discussed as they are applied to the char-
acterization of the metabolites of Compound A,
tolcapone, and various other literature examples.
Q-Trap technology is a must for drug metabolism
laboratories for enabling scientists to make qualita-
tive and quantitative project decisions with confi-
dence.
Chapter 11 “MS Imaging: New Technology Pro-
vides New Opportunities” authored by Michelle
Reyzer and Richard Caprioli describes the use of
mass spectrometry for imaging. Secondary ion mass
spectrometry (SIMS), which has been in use for
imaging surfaces for more than 40 years, is discussed
briefly. The remainder of the chapter is devoted to
matrix assisted laser desorption ionization (MALDI)
based imaging of peptide, proteins, drugs, and me-
tabolites. Over the past five years, advances in instru-
ment design, computer speed/control, and imaging
software, have brought the MALDI-MS imaging tech-
nique out of the academic research laboratories and
into the pharmaceutical research laboratories. The
two most significant advantages for MALDI-MS im-
aging of low molecular weight compounds are thatintact drugs may be analyzed directly from tissues
without the use of isotopic- or radio-label com-
pounds, and metabolites can be differentiated from
the parent drug. The limitations associated with
MALDI-MS for imaging drugs and metabolites di-
rectly from tissue are associated with low mass
region MALDI matrix ions. Details on how to over-
come some of the matrix interference problems and to
prepare tissue samples for MALDI-MS imaging are
well presented with examples, pictorial guides, and
references. These authors clearly show that, in its
current form, MALDI-MS imaging is well suited to
determine the localization of drug compounds and
their metabolites in whole tissue sections. MALDI-MS
imaging is also used in screens for receptor selectiv-
ities of drug candidates without the use of radiola-
beled compounds. This technique is not yet ready for
determining subcellular localization of drugs and
metabolites due to decreased sensitivity when oper-
ating at submicron range resolutions. However, with
improvements in MS technology, laser technology,
and imaging software, applications of MALDI-MS
imaging will indeed increase.
In Chapter 12 “Understanding the Role and Poten-
tial of Infusion Nanoelectrospray Ionization for Phar-
maceutical Bioanalysis”, Bradley Ackerman and Jean-
Marie Dethy provide an excellent overview of the
automated chip-based infusion nanoelectrospray ion-
ization (nanoESI) technology and its applications to
in vitro and in vivo ADME studies. The reader is
introduced to the microfabricated silicon chip based
ESI source (Nanomate) ion formation process as well
as to the inner workings of the source through the use
of excellent descriptions and illustrations. A major
portion of the chapter is devoted to application of the
technology to: (1) non-GLP mode quantification of
analytes in plasma, (2) Caco-2 permeation screening,
(3) metabolic-stability studies, and (4) GLP mode
quantification of analytes in plasma. With each appli-
cation, advantages and limitations of nanoESI-MS are
compared with those of conventional LC-MS/MS
methods. A wealth of information is presented on the
sample preparation techniques for nanoESI bioanaly-
sis as well as less susceptibility of the nanoESI source
to ion suppression compared to ESI at conventional
flow rates. Limitations of using the Nanomate 100 for
bioanalysis include nozzle-to-nozzle failure rate, in-
ability to control the sample plate temperature, lim-
ited array size (10  10), and inability to perform
on-line chromatography. Since the completion of the
book chapter, Advion Biosciences (Ithaca, NY) intro-
duced a new nanoESI source called “Triversa Nano-
mate” and improved the software controlling the
source to alleviate most of the limitations discussed
in this chapter. The new improved source has the
capabilities to do nano flow infusion ESI, LC-nano
flow ESI, and fraction collection. Furthermore, the
array size of the chip has been standardized to 20 
20, and the nozzle-to-nozzle reproducibility in-
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current falls below a set threshold and automatically
switch over to the next nozzle. The added features of
the Advion’s nanoESI source make this technology
important not only for the pharmaceutical ADME
applications described in this chapter but also for
metabolite identification, impurity/degradant identi-
fication, metabonomics, and proteomics. This chapter
is a great starting place for scientists who would want
to learn and benefit from the nanoESI technology.
In summary, the book is a valuable addition to the
library of anyone working in the ADME area. Chem-
ists, biochemists, or pharmaceutical scientists who
wish to obtain an overview of MS applications in
drug metabolism studies should consult this book. In
the first eight chapters, the editor provides a very
useful overview of the application of mass spectro-metric methods to a wide variety of qualitative and
quantitative drug metabolism properties. Different
drug metabolism concepts and their importance in a
drug discovery environment are also covered. In the
last four chapters, state-of-the-art mass spectrometry
technology that can impact discovery and develop-
ment of new medicines are introduced. Each chapter
can be read as a stand-alone chapter, and the reader
is directed to the appropriate chapter of interest by a
fourteen page index. A guide to abbreviations would
have been a useful tool for newcomer. Overall, the
production and editing components of this book are
presented in a very professional manner without any
bias toward any applications, methods, or instrumen-
tations. In addition to being well written, the book is
appropriately priced for academic, governmental,
and the pharmaceutical scientists.
